Quantifying the severity of depressive symptoms in patients with a confirmed diagnosis of Major Depressive Disorder (MDD).
Gold standard for clinical trials and monitoring pharmaceutical treatment response.
Assessing specific somatic vs. psychological symptom clusters (e.g., insomnia, weight loss, agitation).
Evaluating suicidality risk as part of a comprehensive psychiatric review.
Clinical Environment
The HAM-D 17 is a clinician-administered scale. Unlike the PHQ-9, it requires a trained professional to interview the patient and observe non-verbal cues (e.g., psychomotor retardation).
Section 2
Formula & Logic
Severity Stratification
Score 0 – 7
Normal / Remission
Score 8 – 13
Mild Depression
Score 14 – 18
Moderate Depression
Score 19 – 22
Severe Depression
Score ≥ 23
Very Severe Depression
Somatic Focus
The scale places significant weight on physical symptoms: three items are dedicated to insomnia (initial, middle, late), and others assess biological markers such as weight loss and gastrointestinal symptoms.
Section 3
Pearls/Pitfalls
The "Melancholic" Bias
The HAM-D 17 excels at identifying classic melancholic depression but may under-represent "atypical" symptoms such as hypersomnia or hyperphagia.
Practical Tips
Differentiate between "Inhibited" and "Agitated" psychomotor states; both reflect severe illness but present differently.
Item 3 (Suicide) should be explored thoroughly if the patient scores 2 or higher.
Compare scores over time; a 50% reduction from baseline is the standard definition of clinical "Response".
Section 4
Next Steps
Remission and Response
01
Response: Goal is ≥ 50% reduction in total score.
02
Remission: Goal is a score of ≤ 7.
03
Relapse Prevention: If remission is achieved, maintain treatment for at least 6–12 months to prevent recurrence.
04
Adjustment: If < 25% reduction after 4 weeks of optimized dosing, consider switching or augmenting therapy.
Section 5
Evidence Appraisal
Primary Reference
A rating scale for depression
Hamilton M • Journal of Neurology, Neurosurgery, and Psychiatry. 1960;23:56–62. The foundational paper that defined the HAM-D as the clinical benchmark.
Section 6
Literature
Professor Max Hamilton
Developed by Max Hamilton at the University of Leeds. It was the first scale that allowed clinicians to objectively measure changes in a patient's depressive state during the early era of tricyclic antidepressants.
